The Pricing Policy Mirage: Three Signals That Washington’s Drug Cost Crusade Is Reshaping Pharma Strategy Without Fixing Prices
Trump's executive orders and IRA negotiations promise relief, but branded drug prices rose 4.5% in 2024 and U.S. drugs...
biopharma strategy
Chinese Biotechs Shift From Building to Partnering as Deal Values Double
At BIO China, pharma executives and investors debated whether Chinese biotechs should pursue full integration or adopt partnership-led growth...